Erwan Muros-Le Rouzic has more than 20 years’ experience in pharmaceutical industry conducting pharmacoepidemiology and real-world observational research.
He is currently a Senior Principal Scientist for Real-World Data and Pharmacoepidemiology in the field of Neurosciences at F. Hoffmann-La Roche Ltd. He joined the RWD Neuroscience team at Roche in 2018 as the RWD Scientist lead for multiple sclerosis disease area. Since January 2022, he is serving as the RWD Scientist lead for Alzheimer’s disease. Prior to joining Roche, Mr. Muros-Le Rouzic worked at Actelion Pharmaceuticals Ltd. as Associate Director Epidemiology in the field of rare disease in the cardiovascular therapeutic area. He supported clinical development programs of new indications and generated real world evidence for post-approval safety and effectiveness. Prior to Actelion, he worked at Sanofi Pasteur, primarily as a Global Lead Epidemiologist for bacterial meningitis vaccines, developing field studies to monitor changes in the epidemiology of infectious agents and build international partnerships to develop bacterial biobank for early research clinical development programs for new vaccines.
Mr. Muros-Le Rouzic’s interests include epidemiology and pharmacoepidemiology research in infectious diseases, rare diseases and neurosciences, such as the development and conduct of diseases or drug registries, or registries-based studies, particularly in the context of post-marketing requirements and post-approval safety studies. His research has resulted in over 20 publications in peer-reviewed journals (Bibliography PubMed).
Mr. Muros-Le Rouzic received his Master degree in Epidemiology and Public Health from the Public Health and Epidemiology School (ISPED) at the University of Bordeaux, France.